What is HOWL's current stock price?

HOWL (Werewolf Therapeutics, Inc.) is currently trading at $0.44 with a market cap of $21.6M.

What sector is Werewolf Therapeutics, Inc. in?

Werewolf Therapeutics, Inc. (HOWL) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is HOWL a good stock to buy?

Analysts have a Buy consensus on HOWL with a price target of $1.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

HOWL Werewolf Therapeutics, Inc.

Healthcare

$0.44+5.02%ClosedMarket Cap: $21.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.77

P/S

0.00

EV/EBITDA

-0.27

DCF Value

$1.02

FCF Yield

-240.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-208.2%

ROA

-97.0%

ROIC

-103.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-13.5M	$—
Q4 null	$0.00	$-8.4M	$—
FY null	$0.00	$-60.8M	$—
Q3 null	$0.00	$-16.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1.00

Target (Median)

$1.00

Target Range

$1.00 - $1.00

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2025-12-19

B of A SecuritiesBuy

2025-11-18

B of A SecuritiesBuy

2025-08-25

JMP SecuritiesMarket Outperform

2025-08-21

Trading Activity

Insider Trades

View All

EVNIN LUKEdirector

SellWed May 20

EVNIN LUKEdirector

SellWed May 20

EVNIN LUKEdirector

SellWed May 20

EVNIN LUKEdirector

SellWed May 13

RA CAPITAL MANAGEMENT, L.P.10 percent owner

SellTue May 12

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.41

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Peers

CUE